Novartis' MS patent win also a win for Celgene's impending MS drug: analyst

After months of dark skies, the future suddenly looks sunny for Celgene's multiple sclerosis drug.

Celgene's MS treatment ozanimod was in a race to hit the market before Novartis' MS drug Gilenya went off patent. However, the tides have turned after the patent office granted another nine years of exclusivity to Gilenya on Thursday.